Table 2

Crude and adjusted HRs of colorectal cancer associated with the use of acarbose using the Cox model during the follow-up period in the cohort with diabetes

VariablePatients (n)Person-yearsPatients with colorectal cancer (n)Incidence rate per 105 person-years (95% CI)Crude HR (95% CI)Adjusted HR (95% CI)*P value for trend
Total acarbose use
 Nonusers (0 cDDD)199,296735,174.6763103.80 (96.68–111.42)
 Users (>0 cDDD)199,296751,961.156975.70 (69.70–82.15)0.73 (0.66–0.82)0.66 (0.59–0.74)<0.001
  >0 to <90104,281329,996.629790.00 (80.33–100.84)0.86 (0.76–0.99)0.73 (0.63–0.83)
  90 to 36462,714242,982.818274.90 (64.77–86.61)0.74 (0.63–0.87)0.69 (0.59–0.82)
  ≥36532,301178,981.79050.28 (40.90–61.82)0.48 (0.39–0.60)0.46 (0.37–0.58)
  • *Multivariable model with covariates, including age (10-year increment), sex, age of diabetes diagnosis (calendar year), urbanization, income, comorbid disease (hypertension, hyperlipidemia, colon polyps, inflammatory bowel disease, chronic kidney disease), metformin, TZD, insulin, NSAID, statins, surveillance colonoscopy, FOBT, and baseline aDCSI score.